Leonteq Securities’s Harmony Biosciences HRMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$45.1K Buy
1,150
+350
+44% +$13.5K ﹤0.01% 796
2026
Q2
$29.1K Hold
800
– – ﹤0.01% 909
2026
Q1
$22.4K Hold
800
– – ﹤0.01% 978
2025
Q4
$29.9K Buy
800
+200
+33% +$6.58K ﹤0.01% 1037
2025
Q3
$16.5K Buy
600
+200
+50% +$6.89K ﹤0.01% 1061
2025
Q2
$12.6K Hold
400
– – ﹤0.01% 1035
2025
Q1
$13.3K Hold
400
– – ﹤0.01% 1022
2024
Q4
$13.8K Sell
400
-400
-50% -$13.7K ﹤0.01% 1016
2024
Q3
$32K Hold
800
– – ﹤0.01% 842
2024
Q2
$24.1K Buy
+800
New +$24.1K ﹤0.01% 898
2023
Q3
– Sell
-2,295
Closed -$80.8K – 1242
2023
Q2
$80.8K Buy
2,295
+1,925
+520% +$66.5K ﹤0.01% 729
2023
Q1
$12.1K Hold
370
– – ﹤0.01% 990
2022
Q4
$20.4K Hold
370
– – ﹤0.01% 966
2022
Q3
$16.4K Hold
370
– – ﹤0.01% 982
2022
Q2
$18K Hold
370
– – ﹤0.01% 992
2022
Q1
$18K Hold
370
– – ﹤0.01% 1018
2021
Q4
$15.8K Buy
+370
New +$14.7K ﹤0.01% 1098

Other funds holding HRMY

Leonteq Securities's HRMY Position: Q3 2026 in Review

Leonteq Securities increased its Harmony Biosciences (HRMY) stake by 44% in Q3 2026, buying an estimated $13.5K and bringing the position to 1,150 shares worth $45.1K. The position accounts for ﹤0.01% of the portfolio, ranked #796.

Leonteq Securities first reported a position in HRMY in Q4 2021 and has held it in 17 quarters since. The position peaked at $80.8K in Q2 2023. 285 funds tracked by Wall St. Rank hold HRMY as of Q3 2026.

  • Leonteq Securities held 1,150 shares of Harmony Biosciences worth $45.1K as of Q3 2026.
  • Leonteq Securities bought 350 Harmony Biosciences shares in Q3 2026, an estimated $13.5K.
  • Harmony Biosciences made up ﹤0.01% of Leonteq Securities's portfolio in Q3 2026, its #796 holding.
  • Leonteq Securities first reported a position in Harmony Biosciences in Q4 2021 and has held it in 17 quarters since.
  • Leonteq Securities's Harmony Biosciences position peaked at $80.8K in Q2 2023.
  • 285 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2026.

Based on Leonteq Securities's 13F filing for Q3 2026, filed 29 Oct 2026.